Skip to main content

Fiscal Wizard · Single-issue tearsheet

RIGL / Jun 20, 2026 Run #7181

RIGL

Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Composite verdict

D 42.9 / 100
Bearish setup · Reversal 13 drivers · 3 gates blocking
  • Accumulation/Distribution Line
  • Stochastic Cross
  • Engulfing
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 99th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 19 signals100% Bear
Momentum Neutral 49Mean-reversion Bearish 8

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -21%
Asset value $21.16Earnings power value $58.88Price $32.91

The discount is mostly unpriced earnings power: price ($32.91) sits between asset value ($21.16) and no-growth earnings power value ($58.88).

Fundamentals Strong

85.3 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
OCF to Net Income 0
Revenue Growth (YoY) 100
Cash Conversion 0
Earnings Yield 100
Cash Conversion Cycle 0

Technicals Bearish

0.4 / 100

Bearish setup leads (Accumulation/Distribution Line, Stochastic Cross, Engulfing); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Stochastic RSI 12
Accumulation/Distribution Line 12
Wedge Pattern 15

Risk Gates

3 blocking 6 caution

3 guards active, 22 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Altman Z-Score Caution

Bottom-band Altman Z blocks bullish signals — distress risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for RIGL.